GlobeNewswire

Shorter GMAT Exam Launches on April 16

Del
Candidate-Friendly Change Designed to Enhance Test-Taking Experience
 
RESTON, Va., April 04, 2018 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC) is shortening the length of the GMAT exam by 30 minutes as part of its ongoing focus on creating the best possible testing experience and offering user-friendly features. The new, shorter exam - 3.5 hours instead of 4 - will be available for test-takers worldwide beginning April 16. 

The quality of the exam remains unchanged in terms of reliability, validity, security and integrity. GMAT scores before and after this change will be the same and comparable across time.

"We are always looking for ways to help build candidate confidence and streamline the test experience, all with one goal in mind-to help GMAT test-takers do their very best on exam day," said Vineet Chhabra, senior director of product management for GMAC. "We believe candidates will have less anxiety and feel better prepared, which can contribute to a better reflection of their true performance on the exam."

The time savings are achieved by streamlining the two longer sections of the exam, the Quantitative and Verbal Reasoning sections, reducing the number of unscored, research questions in these sections. Several tutorial and instruction screens that test-takers see at the test center have also been simplified. There are no changes to the exam's Analytical Writing or Integrated Reasoning sections. The way the GMAT exam is scored, the content of the exam, the question types and the average time per question are not changing.

"Through our ongoing market feedback and operational reviews, we were able to identify this opportunity to shorten the exam, without changing its reliability," said Chhabra. "This change will not affect GMAT exam scoring as the number of scored questions will not change. The scoring algorithm will be the same; the Total Score and individual Quantitative and Verbal section scores will be comparable to the exams taken prior to this change. There is no action or change required on the part of business schools and universities. We are providing candidates with a better testing experience, while providing business schools with the same high quality, fair and reliable scores."

Along with these changes, GMAC is providing a new, online tutorial that mimics the screens that test-takers see on exam day, further enhancing and streamlining the test center experience. By moving the tutorial information online, to www.mba.com/, test takers can access it prior to arriving at the test center, at their convenience and as often as they wish.

The GMAT exam is designed to showcase the skills that are most relevant to the world's leading graduate business programs; 9 out of 10 new MBA enrollments globally are made using a GMAT score. 

To align with the changes, GMAC is launching new GMAT Official Prep tools to match the structure of the shorter exam. The GMAT Official Practice Exams and Practice Questions will be available on an online platform for better ease-of-use, as well as some feature improvements such as single sign-on and ability to access prep materials across multiple devices. GMAT Official Prep tools are the only official source of retired GMAT questions, and the Council's research shows that candidates who use official products score an average of 18 percent higher on the GMAT exam than those who don't. The updated practice tools will be available by the end of April.    

These changes are part of a series of candidate-friendly enhancements to the GMAT exam in recent years, all focused on improving the testing experience, including: 

  • Exam section order selection at the testing center (Select Section Order)
  • Making unofficial scores available immediately, before leaving the test center following the exam
  • Updates to score cancellation and reinstatement options

To learn more about these changes, please review our FAQs: http://www.mba.com/global/frequently-asked-questions/shorter-gmat-exam

About GMAC: The Graduate Management Admission Council (GMAC) is a global, non-profit association of 223 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®) exam, used by more than 7,000 graduate programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive MBA programs around the world. The Council is based in the United States with offices in London, New Delhi (Gurugram), and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com.

MEDIA CONTACT: Tania Hernandez-Andersen, GMAC Sr. Dir. of Corporate Brand Communications, thernandez-andersen@gmac.com or 703-668-9638 (office), 571-294-4059 (mobile).




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CETPressemelding

On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months

Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CETPressemelding

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera

Mattson Technology Announces Hydrilis™, a Unique High-Productivity Vacuum Wafer Process Platform18.3.2019 17:00:00 CETPressemelding

– Up to 4 process chambers and 8 wafer processing stations – – Smallest footprint, highest throughput platform – – Enables any process chamber, any position configuration flexibility – FREMONT, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Mattson Technology, Inc., a leading supplier of advanced process equipment used to manufacture semiconductors, introduces Hydrilis™, the industry’s highest productivity density vacuum transfer platform featuring high throughput on the smallest footprint. The Hydrilis platform can be configured with up to 4 process chambers, or 8 processing stations, for parallel or sequential wafer processing. Any of the paradigmE® family plasma etch process chambers, Suprema® family plasma photoresist strip and hard-mask removal process chambers, Novyka™ family surface treatment process chambers and Novyka family selective chemical dry etch process chambers can all be integrated on the Hydrilis platform. “Throughput per unit area of fab space is one of the key criteria

Minerva Neurosciences to Host Webcast Event on Schizophrenia18.3.2019 13:30:00 CETPressemelding

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a webcast, “Schizophrenia: Disease Landscape and Forecast,” on Thursday, March 21, 2019 beginning at 10:00 a.m. eastern time in Boston, MA. Minerva’s Executive Chairman and Chief Executive Officer, Remy Luthringer, Ph.D., will be joined by representatives from Decision Resources Group, a global information and technology services company providing proprietary data and solutions to the healthcare industry, and Dr. Gregory Strauss, an expert key opinion leader. Discussions will feature the following speakers

Infovista Enhances Ipanema SD-WAN with Nextgen Application Intelligence+ and Cloud-Native Orchestration18.3.2019 13:00:00 CETPressemelding

PARIS and ASHBURN, Va., March 18, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new cloud-native management and control with next-generation Application Intelligence+ for Ipanema SD-WAN, delivering unmatched application performance across any WAN. Tweet This: Infovista enhances Ipanema SD-WAN with nextgen Application Intelligence+ and cloud native orchestration: https://bit.ly/2ULcKLW #SmarterSDWAN The enterprise network has become the central nervous system of modern digital businesses, and SD-WAN is enabling this digital transformation. Infovista’s Ipanema SD-WAN with new cloud-native management and control of applications tightly combines session-based routing and dynamic path selection of the underlay network with an overlay of deep application visibility and dynamic control of the quality of experience for business-critical applications. Additionally, Ipanema automatically understands application delivery requirements and maintains a

Inspirata and Ohio State University Continue to Break Digital Pathology Barriers18.3.2019 12:30:00 CETPressemelding

Columbus, Ohio Columbus, Ohio, March 18, 2019 (GLOBE NEWSWIRE) -- Less than one year ago Inspirata announced that their digital pathology solution was used to make the first-ever primary digital diagnosis in the U.S., initiating a new era in cancer diagnostics. Today, cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced the company with the help of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has broken another barrier- Inspirata and the OSUCCC – James have scanned over one-million anatomic pathology slides into high resolution whole slide digital images. “This historic accomplishment has demonstrated that it is possible to create large repositories of diagnostic quality prospective and retrospective slides creating imaging data that will accelerate clinical and research efforts,” says Inspirata Scan Center Manager, Trina Shanks, MLT (ACSP), CPC. Inspirata will presen